NCT07755423Enrolling by invitation
Stereotactic Body Radiotherapy for the Treatment of Distant Metastases in Thyroid Cancer: A Phase II Prospective Clinical Study
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
The goal of this observational study is to evaluate the efficacy and safety of Stereotactic Body Radiotherapy in the treatment of distant metastatic thyroid cancer.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 44 (estimated)
- First submitted
- 5 Aug 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- Fudan University
- Diseases
- Thyroid cancer
- NCT number
- NCT07755423
What you commit to
- Study type: Observational
- Planned participants: 44
- From 1 Apr 2026 to the primary completion date, 31 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received radiotherapy to the corresponding area and the radiotherapy site overlapped with this one.
- Severe internal medical complications and contraindications to radiotherapy.
Other illness
- Uncontrollable malignant pleural or peritoneal effusion.
- Active mental disorders or other psychological disorders that affected the patient's signing of informed consent and understanding ability.
- Uncontrollable infections or active infections, such as immunodeficiency or AIDS patients.
Age
- Pregnant women of childbearing age with positive pregnancy test or lactating women.
Other
- Patients who achieved complete remission after comprehensive treatment.
- Pathologically confirmed as a second primary tumor.
Who the study is looking for
- Participants with primary lesion pathologically confirmed as thyroid cancer, and distant metastatic lesions confirmed either by pathology or by two types of imaging modalities. Based on the investigator's judgment, the participant's distant metastatic lesions are expected to be tolerable to Stereotactic Body Radiotherapy (SBRT). The distant metastases should be oligometastatic (total number of metastatic lesions ≤ 5).
- Participants who have failed prior systemic therapy. Systemic therapy includes radioactive iodine therapy, immunotherapy, targeted therapy, clinical trial therapy, etc.
- Age: 18 - 70 years old.
- KPS ≥ 70.
- Expected survival period ≥ 3 months.
- Before treatment, neutrophils ≥ 1.6 × 109/L, hemoglobin ≥ 80g/L, platelets ≥ 80×109/L; creatinine clearance rate ≥ 60 ml/min; non-hepatic metastasis patients (total bilirubin ≤ 1.5 times the upper limit of normal, ALT ≤ 1.5 times the upper limit of normal, AST ≤ 1.5 times the upper limit of normal), hepatic metastasis patients (total bilirubin ≤ 3 times the upper limit of normal, ALT ≤ 3 times the upper limit of normal, AST ≤ 3 times the upper limit of normal, normal coagulation function, Child-Pugh grade A or B, normal liver tissue volume \> 700 mL)
- Signed informed consent form and willing to complete the study according to the protocol.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.